Related references
Note: Only part of the references are listed.In silico identification of inhibitors of ribose 5-phosphate isomerase from Trypanosoma cruzi using ligand and structure based approaches
Vanessa de V. C. Sinatti et al.
JOURNAL OF MOLECULAR GRAPHICS & MODELLING (2017)
Disclosing the essentiality of ribose-5-phosphate isomerase B in Trypanosomatids
Joana Faria et al.
SCIENTIFIC REPORTS (2016)
Studies of genotoxicity and mutagenicity of nitroimidazoles: demystifying this critical relationship with the nitro group
Nubia Boechat et al.
MEMORIAS DO INSTITUTO OSWALDO CRUZ (2015)
Ribose 5-Phosphate Isomerase B Knockdown Compromises Trypanosoma brucei Bloodstream Form Infectivity
Ines Loureiro et al.
PLOS NEGLECTED TROPICAL DISEASES (2015)
The Reliability of Estimating Ki Values for Direct, Reversible Inhibition of Cytochrome P450 Enzymes from Corresponding IC50 Values: A Retrospective Analysis of 343 Experiments
Lois J. Haupt et al.
DRUG METABOLISM AND DISPOSITION (2015)
Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity
Bianca Zingales et al.
MEMORIAS DO INSTITUTO OSWALDO CRUZ (2014)
Novel amidines and analogues as promising agents against intracellular parasites: a systematic review
M. N. C. Soeiro et al.
PARASITOLOGY (2013)
Structures of type B ribose 5-phosphate isomerase from Trypanosoma cruzi shed light on the determinants of sugar specificity in the structural family
Ana L. Stern et al.
FEBS JOURNAL (2011)
Structural modelling and comparative analysis of homologous, analogous and specific proteins from Trypanosoma cruzi versus Homo sapiens: putative drug targets for chagas' disease treatment
Priscila V. S. Z. Capriles et al.
BMC GENOMICS (2010)
Chagas' disease: an update on immune mechanisms and therapeutic strategies
Silvia Beatriz Boscardin et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2010)
Aryl Phosphoramidates of 5-Phospho Erythronohydroxamic Acid, A New Class of Potent Trypanocidal Compounds
Gian Filippo Ruda et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Homology modeling in drug discovery: current trends and applications
Claudio N. Cavasotto et al.
DRUG DISCOVERY TODAY (2009)
Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities
Rodolfo Viotti et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2009)
IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding
R. Z. Cer et al.
NUCLEIC ACIDS RESEARCH (2009)
A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes
Shane R. Wilkinson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Genomic minimalism in the early diverging intestinal parasite Giardia lamblia
Hilary G. Morrison et al.
SCIENCE (2007)
Synthesis and biological evaluation of phosphate Prodrugs of 4-Phospho-D-erythronohydroxamic acid, an inhibitor of 6-phosphogluconate dehydrogenase
Gian Filippo Ruda et al.
CHEMMEDCHEM (2007)
Ribose 5-phosphate isomerase type B from Trypanosoma cruzi: kinetic properties and site-directed mutagenesis reveal information about the reaction mechanism
Ana L. Stern et al.
BIOCHEMICAL JOURNAL (2007)
Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis)
Jose A. Castro et al.
HUMAN & EXPERIMENTAL TOXICOLOGY (2006)
Estimating the cost of new drug development: Is it really $802 million?
CP Adams et al.
HEALTH AFFAIRS (2006)
Synthesis and evaluation of new 4-phospho-D-erythronic acid derivatives as competitive inhibitors of spinach ribose-5-phosphate isomerase
E Burgos et al.
TETRAHEDRON LETTERS (2004)
Share Paper
